whereas total cholesterol increased in both groups with no difference between groups. Conclusions Our study, carried out in a selenium-sufficient cohort of GD patients, failed to show an adjuvant role of selenium in the short-term control of hyperthyroidism. However, selenium might be beneficial in patients from selenium-deficient areas, as well as in the long-term outcome of antithyroid treatment.
Introduction
The trace mineral selenium is an essential nutrient contained in various foods, both as inorganic and organic forms [1, 2] . Selenium exerts its functions after incorporation into several selenoproteins, including glutathione peroxidase (GPX), thioredoxin reductase and iodothyronine deiodinase, all of which have enzymatic functions [1] [2] [3] [4] [5] [6] . In GPX, selenium is located on the catalytic site, being an essential component of the antioxidant action of the enzyme [1] [2] [3] [4] [5] [6] . Thus, GPX is involved in protection from oxidative stress as it reduces H 2 O 2 into H 2 O. Also thioredoxin reductase has antioxidant functions and, overall, selenium acts as a reduction-oxidation center, thereby exerting important antioxidant actions [1] [2] [3] [4] [5] [6] .
Once introduced with the diet, selenium is absorbed in the gastrointestinal tract and transported to the liver, where it binds to several glycoproteins, resulting in the formation of selenoglycoproteins that can contain up to 10 selenium residues per molecule [1] [2] [3] [4] [5] [6] . Selenoglycoproteins then reach the circulation, to finally be transported to peripheral
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Cereals, meat, vegetables and dairy products are the types of food that contain the highest quantities of selenium. The US Food and Nutrition Board recommends a daily intake of selenium of 50-200 μg as adequate, in order to reach an optimal level of serum atomic selenium of ~100 μg [1] [2] [3] [4] [5] [6] [7] . However, selenium serum values in population studies have often been found to be lower than the recommended levels, and selenium deficiency has been included among the causes of oxidative stress-related diseases [1] [2] [3] [4] [5] [6] [7] .
Recently, a possible therapeutic role of selenium has been proposed for the management of thyroid disorders, including chronic autoimmune thyroiditis and Graves' hyperthyroidism and orbitopathy [8] [9] [10] [11] [12] . Oxidative stress is believed to play an important role in hyperthyroidism [13] [14] [15] [16] ). The hypermetabolic state typical of hyperthyroidism causes the release of large amounts of reactive oxygen species (ROS) in peripheral tissues [14, 15] , as shown by studies in hyperthyroid animals and patients with Graves' disease (GD) [16, 17] . Interestingly, ROS release occurs also in the thyroid gland [16, 17] . Therefore, it has been proposed that in GD ROS might actually act at two levels. First, in the thyroid they may cause thyrocyte damage, resulting in increased autoantigen exposure to the immune system and worsening of autoimmunity. In peripheral tissues ROS may be responsible tissue damage, thereby contributing to the clinical manifestations of hyperthyroidism. The role of ROS in hyperthyroidism in general and in GD in particular would be especially relevant under conditions of selenium deficiency, when the counteracting action of selenium may be insufficient. To address this issue, a few studies have been conducted in the past, in which hyperthyroid patients were supplemented with selenium, alone or within a mixture of antioxidant compounds, in addition to antithyroid drug treatment [16, 18, 19] . Although some results were encouraging, findings were quite variable. For this reason, we performed a randomized clinical trial aimed at investigating weather selenium supplementation is beneficial for the short-term control of newly diagnosed GD hyperthyroidism treated with methimazole (MMI).
Subjects and methods

Study design and outcomes
The randomized clinical trial was performed in two groups of newly diagnosed GD patients, treated either with selenium and MMI, or with MMI only.
The primary outcome measures of the study were: (i) control of hyperthyroidism, namely FT 3 and FT 4 serum levels, at 90 days; (ii) clinical and other biochemical manifestations of hyperthyroidism, namely heart rate, body weight, total serum cholesterol, sex hormone-binding globulin (SHBG) and a score of hyperthyroidism symptoms collected by questionnaire, at 90 days.
The secondary outcome measures were: (i) control of hyperthyroidism at 45 days; (ii) clinical and other biochemical manifestations of hyperthyroidism at 45 days; (iii) serum selenium levels at 45 and 90 days; (iv) serum concentration of malondialdehyde (MDA), an oxidative stress parameter, at 45 and 90 days; and (v) adverse events of selenium at 45 and 90 days.
Study registration and approval
The study was approved by the local Review Board (Comitato Etico Area Vasta Nord Ovest, Board Affiliation: Comitato Etico Regionale per la Sperimentazione Clinica, Approval Number: 3804). The study was registered at ClinicalTrials.gov (Registration Number: NCT02727738).
Inclusion and exclusion criteria
Inclusion criteria were: (i) untreated hyperthyroidism due to GD. The diagnosis of hyperthyroidism was based on the presence of high serum FT4 (≥17 pg/ml) and/or FT3 (≥5.7 pg/ ml) and low serum TSH (≤0.4 mU/l) levels. The diagnosis of GD was based on the presence of a diffuse goiter and detectable serum TSH receptor antibodies (TRAb); (ii) informed consent; (iii) absence of exclusion criteria. Exclusion criteria were: (i) previous or concomitant treatments for hyperthyroidism by any means; (ii) lack of informed consent; (iii) conditions that can affect oxidative stress, namely diabetes, ischemic heart disease, liver or kidney failure, alcoholism, smoking; (iv) treatment with selenium or other antioxidant agents.
Drop out
Patients could exit from the study at any time, or under the following circumstances: (i) lack of response to MMI; (ii) adverse events that prompted cessation of treatment; and (iii) lack of compliance to treatment and assessments. Patients who interrupted the study after the assessment at 45 days were included in an intent-to-treat analysis.
Patients and randomization
Based on previous studies on similar issues in which a 45 % difference between study groups was observed for some of the parameters included here as primary outcomes [19] , a total number of 30 patients, 15 per group, were estimated to provide a statistically significant difference (P ≤ 0.05), with a statistical power of 0.8, considering a 10 % drop-out rate. Therefore, 30 consecutive patients with GD who met the inclusion criteria were included, 3 men and 27 women (age 40 ± 11 years, range 19-65 years). Patients were randomized in blocks of six into: (i) MMI; or (ii) MMI-selenium.
Intervention
Patients in both groups were treated with MMI at doses based on FT 3 levels as follows: (i) for FT 3 levels ≥5.7 and <10 pg/ml: 15 mg/day for 15 days, 10 mg/day for 15 days, and 5 mg/day for 15 days, followed by dose adjustment based on FT 3 and TSH levels; (ii) for FT 3 levels ≥10 and <15 pg/ml: 20 mg/day for 15 days, 15 mg/day for 15 days, and 10 mg/day for 15 days, followed by dose adjustment as above; (iii) for FT 3 levels ≥15: 30 mg/day for 15 days, 20 mg/day for 15 days, and 15 mg/day for 15 days, followed by dose adjustment as above. Treatment with MMI was continued for all the duration of the study.
Patients in the MMI-selenium group were also given l-selenomethionine (©Syrel, IBSA Farmaceutici Italia, Lodi, Italy) 2 tablets/day for 90 days, corresponding to 166 μg/day of l-selenomethionine.
Patient evaluation
All patients underwent the following assessment and measurements at baseline, 45 and 90 days: (i) physical evaluation; (ii) thyroid ultrasound (only at baseline) with calculation of thyroid volume according to the ellipsoid formula [20] ; (iii) blood: FT 4 and FT 3 (Vitros Immunodiagnostics, Raritan, NJ); TSH (Immulite 2000, Siemens Healthcare, Gwynedd, UK); TRAb (RSR Ltd Cardiff, UK); total cholesterol (Roche, Mannheim, Germany); SHBG (Beckman Coulter Italia, Cassina de Pecchi, Italy); selenium (by atomic absorption spectroscopy); and MDA (Sigma-Aldrich, St. Louis, MO); (iv) body weight; (v) heart rate, measured by ECG; and (vi) questionnaire on hyperthyroidism symptoms. The latter was developed arbitrarily and administered to patients. Six symptoms of hyperthyroidism were considered, including nervousness and irritability, insomnia, diarrhea, sweating, heat intolerance and tremors. For each symptoms, a score from one to three points was assigned as follows: (i) nervousness and irritability: 1: absent/normal; 2: more often than usual; 3: much more often than usual; (ii) insomnia: 1: absent; 2: occasional (one-two nights in the last month); 3: frequent (more than two nights in the last month); (iii) diarrhea: 1: absent; 2: occasional (one-two times in the last month); 3: frequent (more than two times in the last month); (iv) sweating: 1: absent/normal; 2: slightly increased; 3: very frequent/profuse; (v) heat intolerance: 1: absent/normal; 2: slightly increased; 3: markedly increased; and (vi) tremor: 1: absent; 2: mild; 3: marked. A final score, ranging fro 6 to 18, was obtained by summing the values of each symptom.
Data presentation and statistical analyses
Descriptive data were normally distributed, which was assessed using the Wilks-Shapiro test, and are presented as mean ± SD unless otherwise specified. TRAb values, that were not normally distributed, are presented as median and IQR. The following statistical tests were performed, as appropriate: (i) t test; (ii) Mann-Whitney; (iii) repeated measures ANOVA.
Results
Comparison of groups at enrollment
Demographic, clinical and biochemical features of the two groups at baseline are illustrated in Table 1 . None of the parameters under examination (gender, age, thyroid volume, FT 3 , FT 4 , TRAb, serum selenium, serum MDA, body weight, heart rate, SHBG, total cholesterol and hyperthyroidism symptom score) differed statistically between the two groups. One patient per group left the study for 
Selenium levels and oxidative status
As reported above and in Table 1 , serum selenium levels at baseline were similar in the two groups. Mean selenium levels were within the recommended range to define selenium sufficiency [1] [2] [3] [4] [5] [6] [7] . As shown in Fig. 1a and as expected, serum selenium levels during treatment increased significantly in the MMI-selenium group, and became significantly higher than those in the MMI group. Serum MDA values were similar in the two groups at baseline (Table 1 and Fig. 1b) , and decreased significantly and to the same extent in the two groups during treatment, both at 45 and 90 days (Fig. 1b) .
Thyroid function and manifestations of hyperthyroidism
Administration of MMI was followed in both groups by a significant reduction in both FT 3 ( Fig. 2a) and FT 4 ( Fig. 2b) concentrations, with no significant differences between the two study groups. Mean body weight remained stable during the observational period in both groups and was not affected by selenium (Fig. 3a) . Heart rate decreased significantly to the same extent in both groups during MMI treatment (Fig. 3b) . Likewise, serum SHBG decreased significantly and serum cholesterol increased significantly in the two groups, reflecting correction of hyperthyroidism by MMI (Fig. 3c, d ), but selenium did not affect these parameters either. As shown in Fig. 3e , the hyperthyroidism symptom score decreased significantly in both groups during MMI treatment, with no difference between groups.
Discussion
The present randomized clinical trial was performed to investigate whether selenium supplementation might have a beneficial effect on the short-term control of hyperthyroidism in patients with newly diagnoses Graves' hyperthyroidism treated with MMI. This investigation was prompted by the conflicting results present in the few reports available in the literature. Vrca et al. [18] showed that a relatively low dose of selenium (60 μg/day), part of a mixture of antioxidants including β-carotene, Vitamin C and Vitamin E given concomitantly with MMI, was associated with a better response to treatment in terms of LDL cholesterol increase compared with patients given MMI only, although there were no apparent advantages concerning control of thyroid function. We also found that selenium addition to MMI did not offer any advantage in terms of prompter or better control of thyroid hyperfunction. Guerra et al. [16] also used an antioxidant mixture containing a small amount of selenium (15 μg) associated daily with MMI, and found a better biochemical and clinical control of hyperthyroidism in patients given this mixture compared with MMI alone. This is surprising, since we were unable to show any effect using much larger daily amounts of selenium (166 μg). The lack of knowledge on the selenium status in patients in Guerra et al.'s study, the use of an antioxidant mixture, and the different follow-up schedule 3 a Body weight at time 0, and then after 45 and 90 days, in patients treated with methimazole (MMI) or with MMI plus selenium (MMI-selenium). *P = NS within and between groups by repeated measures ANOVA; b Heart rate. *P < 0.0001 within the MMI group and **P < 0.0001 within the MMI-selenium group by repeated measures ANOVA; P = NS between the two groups; c Serum sex hormone-binding globulin (SHBG). *P = 0.0009 within the MMI group and **P = 0.0031 within the MMI-selenium group by repeated measures ANOVA; P = NS between the two groups; d Serum cholesterol. *P < 0.0001 within the MMI group and **P < 0.0001 within the MMI-selenium group by repeated measures ANOVA; P = NS between the two groups; e Symptom score obtained by questionnaire. *P < 0.0001 within the MMI group and **P < 0.0001 within the MMI-selenium group by repeated measures ANOVA; P = NS between the two groups (4-8 weeks compared with 45-90 days in our study), do not allow a fair comparison with our study. The only previous study in which "pure" selenium, rather than a mixture of antioxidants, was used as in our study, was performed by Calissendorff et al. [19] , who obtained quite different results. A selenium-deficient (serum selenium ~50 ng/ml) cohort of hyperthyroid patients was randomized to receive MMI and levothyroxine (block-and-replace regimen), either associated with placebo or with selenium (200 μg/day). At variance with our negative results, a beneficial effect of selenium in terms of biochemical control of thyroid hyperfunction was observed [19] The most likely explanation to reconcile these conflicting results, besides the different antithyroid drug treatment regimen, resides is the different selenium status of patients. Quite unexpectedly, our patients were seleniumsufficient, and although selenium administration led to an increase in serum selenium levels, this did not affect oxidative stress, as assessed by serum MDA levels, which were reduced to the same extent by MMI in both study groups. It is conceivable that in our cohort of patients the antioxidant action of selenium was probably already maximal at baseline, and could not increase further. In keeping with this explanation, serum MDA levels were previously shown to decrease during selenium treatment in presumably seleniumdeficient subjects (17) .
In conclusion, our study shows that selenium supplementation does not offer any advantage in terms of shortterm control of hyperthyroidism if selenium intake is adequate. Selenium is likely useful if the patient is selenium-deficient. We, therefore, suggest that the patient's selenium status should be evaluated prior to institution of antithyroid drug treatment, to assess if the individual patient may benefit from selenium supplementation. The latter is, in any case indicated, if the patient has associated, mild Graves' orbitopathy [12] . Whether selenium supplementation may be beneficial for the long-term outcome of antithyroid drug treatment (remission vs. relapse) remains to be ascertained.
